World's first dual-chamber leadless pacemaker receives FDA approval for cardiac arrhythmia

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-07-07 06:00 GMT | Update On 2023-07-07 11:06 GMT

USA: The US FDA (Food and Drug Administration) has approved the first chamber leadless pacing system, Aveir DR dual-chamber leadless pacemaker, for treating people with abnormal or slow heart rhythms.

"With more than 80% of people needing a pacemaker requiring pacing in two chambers of the heart (both the right atrium and right ventricle), the approval significantly increases access to leadless pacing for millions across the US," stated the company's press release.

Abbott's Aveir DR system comprises two small single-chamber pacemakers: the new Aveir AR pacemaker for the right atrium and the previously approved Aveir VR for the right ventricle.

Both leadless implants are paired for beat-to-beat, wireless communication via Abbott's proprietary "i2i technology" that relies on the power generated through a person's blood. Abbott states these high-frequency pulses use less battery than inductive, radiofrequency, or Bluetooth communication.

"Modern medicine has been filled with technological achievements that fundamentally changed how doctors approach patient care, and now we can officially add dual chamber leadless pacing to that list of achievements," said Vivek Y. Reddy, MD, director of cardiac arrhythmia services for the Mount Sinai Hospital and the Mount Sinai Health System, stated in the press release.

Dual-chamber pacing is indicated for patients with sick sinus syndrome; recurrent Adams-Stokes syndrome; chronic, symptomatic second- and third-degree AV block; and symptomatic bilateral bundle-branch block when tachyarrhythmia and other causes have been ruled out.

Both Aveir pacemakers are smaller than a AAA battery and are implanted percutaneously. The device is attached to the heart's interior surface via a helical screw-in mechanism to facilitate future device removal.

The device's approval was based on the Aveir DR i2i study that found that 0.2% of patients met the device's primary endpoint of adequate atrial capture threshold and sensing amplitude at three months. The implant success rate was 98.3%, and more than 97% of people had a successful atrioventricular synchrony at three months.

Device recipients showed 90.3% freedom from device- or procedure-related serious adverse events at 90 days. Complications included serious cardiac injury events, atrial fibrillation, and intraprocedural dislodgements of a leadless pacemaker.

"Leadless pacemakers have been limited to a single chamber device because seamless, wireless synchronization of two pacemakers has been an insurmountable engineering challenge - until now," said Randel Woodgrift, senior vice president of Abbott's cardiac rhythm management business. "Our team of dedicated scientists and engineers solved one of medtech's complex challenges in treating abnormal heart rhythms with the AVEIR pacemaker, a tiny device packed with powerful technology."

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Medha Baranwal

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

World's first dual-chamber leadless pacemaker receives FDA approval for cardiac arrhythmia

Similar News

Tirzepatide Matches dulaglutide in Heart Protection, Offers Added Benefits in SURPASS-CVOT trial

Subclinical Primary Aldosteronism Raises Risk of MACE Even With Normal BP, Suggests Study

Brisk Walking Just 15 Minutes a Day May Cut Death Risk by 20 Percent: Study Finds

Kidney Injury Significantly Increases Hypertension Risk, Study Finds

Medical Bulletin 31/July/2025

Study compares common type 2 diabetes drugs, finding higher cardiovascular risk for one medication: JAMA

Ventricular Arrhythmias in Sarcoidosis Linked to Triple Mortality Risk and Higher Device Implantation Rates: Study

Exercise Rehab Eases Irregular Heart Rhythm and Improves Mental Health: Study Finds